- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01604291
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Afula, Israel, 18101
- Haemek Hospital; Gastroenterology
-
Ashkelon, Israel, 78278
- Barzilai MC; Gastroenterology
-
Beer Sheva, Israel, 84105
- Soroka Medical Center; Gastroenterology
-
Hadera, Israel, 38100
- Hillel Yaffe Hospital; Gastroenterology
-
Haifa, Israel, 31096
- Rambam Medical Center; Gastroenterology - Liver Unit
-
Haifa, Israel, 33394
- Bnei-Zion Medical Center; Gastroenterology
-
Haifa, Israel, 34362
- Carmel Hospital; Liver Unit
-
Holon, Israel, 58100
- Wolfson Hospital; Gastroenterology Unit
-
Jerusalem, Israel, 91031
- Shaare Zedek Hospital Liver Unit; Liver Unit
-
Jerusalem, Israel, 91120
- Hadassah Hospital; Liver Unit
-
Kfar Saba, Israel, 44281
- Meir Medical Center; Liver Unit
-
Nahariya, Israel, 22100
- Western Galilee Hospital - Nahariya
-
Nazareth, Israel
- Holy Family Medical Center; Liver Unit
-
Petach Tikva, Israel
- Hasharon Mc; Gastroenterology
-
Petah Tiqwa, Israel
- Beilinson-Rabin Liver Unit; Liver Unit
-
Ramat Gan, Israel, 5262100
- Sheba Medical Center; Tel Hashomer
-
Rehovot, Israel, 76100
- Kaplan Medical Center; Gastroenterology Unit
-
Safed, Israel, 13110
- Rebecca Sieff Medical Center; Liver Unit
-
Tel Aviv, Israel, 6423906
- Tel-Aviv Sourasky Medical Center; Liver Unit
-
Tiberias, Israel
- Poria Hospital; Gastroenterology
-
Zerifin, Israel, 6093000
- Assaf Harofeh; Gastroenterology
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected or HCV-HIV co-infected)
- Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus ribavirin plus telaprevir/boceprevir)
- No contra-indications to Pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local Prescribing Information
- Quantitative serum HCV RNA by PCR test before initiation of treatment
Exclusion Criteria:
- Hepatitis A/B co-infection
- Evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- Pregnant or breast-feeding women
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
---|
Kohorte
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants With Sustained Viral Response (SVR) at Week 24
Zeitfenster: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
|
Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Comparison of SVR at Week 24
Zeitfenster: Week 24
|
SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.
|
Week 24
|
Number of Participants With SVR at Week 24 According to the Demographic Characteristics
Zeitfenster: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
Number of participants analysed signifies participants who were evaluated for outcome measure.
Data for this outcome measure was not summarized for each arm.
Hence, data is reported for all participants.
|
Week 24
|
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
Zeitfenster: Week 4
|
RVR was defined as HCV-RNA <50 IU/mL by Week 4
|
Week 4
|
Percentage of Participants With Extended RVR
Zeitfenster: Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Extended RVR was defined as HCV-RNA <50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 & 24 for participants treated with boceprevir. The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'. |
Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Percentage of Participants With Complete Early Virologic Response (cEVR)
Zeitfenster: Week 12
|
Complete early virologic response (cEVR) was defined as HCV-RNA <50 IU/mL by Week 12
|
Week 12
|
Percentage of Participants With End of Treatment Response (EoT)
Zeitfenster: Week 24
|
End-of-Treatment (EoT) response was defined as HCV-RNA <50 IU/mL by the end of treatment.
|
Week 24
|
Percentage of Participants With Virologic Relapse
Zeitfenster: Week 72
|
Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA <50 IU/mL at EoT.
|
Week 72
|
Treatment Duration
Zeitfenster: Week 48
|
The average amount of time a treatment was prescribed to participants.
|
Week 48
|
Time to First Dose Modification of Peginterferon Alfa-2a
Zeitfenster: Week 48
|
Week 48
|
|
Time to First Dose Modification of Ribavirin
Zeitfenster: Week 48
|
Week 48
|
|
Time to First Dose Modification of Telaprevir/Boceprevir
Zeitfenster: Week 48
|
Week 48
|
|
Percentage of Participants With Adverse Events (AEs)
Zeitfenster: Week 48
|
Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants. |
Week 48
|
Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia
Zeitfenster: Week 48
|
Week 48
|
|
Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia
Zeitfenster: Week 48
|
Week 48
|
|
Percentage of Participants Who Had SVR at Week 24 With Dose Modifications
Zeitfenster: Week 24
|
Participants with dose modifications who had achieved SVR at Week 24 were reported.
Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.
|
Week 24
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, chronisch
Andere Studien-ID-Nummern
- ML28268
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis C, chronisch
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
Beni-Suef UniversityAbgeschlossenChronische Hepatitis-C-VirusinfektionÄgypten
-
Humanity and Health Research CentreBeijing 302 HospitalAbgeschlossenChronische Hepatitis-C-InfektionChina
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus